Clarus Therapeutics Holdings, Inc. (CRXT) News
Filter CRXT News Items
CRXT News Results
|Loading, please wait...|
CRXT News Highlights
- For CRXT, its 30 day story count is now at 2.
- Over the past 4 days, the trend for CRXT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CRXT are TOP.
Latest CRXT News From Around the Web
Below are the latest news stories about CLARUS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate CRXT as an investment opportunity.
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news on Tuesday morning.
Fans of AMC Entertainment (AMC) stock will want to keep an eye on the company come Sept. 3 as it prepares for a special theater event.
Humanigen (HGEN) stock is heading lower on Monday as investors react to a minimum price delisting notice from the Nasdaq Exchange.
Pinduoduo (PDD) stock is getting a boost on Monday after the Chinese agriculture tech company released results for Q2 2022.
Clarus Therapeutics (CRXT) stock is falling hard on Monday as investors prepare for the stock to be delisted later this week.
We're breaking down the biggest pre-market stock movers and the news that has them rising and falling for Monday morning!
Clarus Therapeutics Holdings (CRXT - Research Report) received a Hold rating and price target from Needham analyst Serge Belanger today. The company's shares opened today at $0.21.Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Amphastar Pharmaceuticals, and Verrica Pharmaceuticals. According to TipRanks, Belanger has an average return of 7.3% and a 48.63% success rate on recommended stocks. Clarus Therapeutics Holdings has an analyst consensus of Hold.See the top stocks recommended by analysts >>The company has a one-year high of $31.24 and a one-year low of $0.20. Currently, Clarus Therapeutics Holdings has an average volume of 3.11M.
We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday and what's moving them!
Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcount; transition of Chief Financial Officer role NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical n
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the U